GlassScriptPhysician profile
Sean S Saedi
NPI 1003896234
$12,490.10
in general payments reported to CMS, 2019-2025
49 companies · $2,123 in 2025
The $2,123 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $1,268 · 2021: $1,570 · 2022: $1,957 · 2023: $2,170 · 2024: $2,260 · 2025: $2,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,474 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,473.63 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,343.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,212.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,071.64 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,024.84 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $957.31 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $760.20 | 2019-2025 | |
| Glaxosmithkline, LLC. | $604.94 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $577.73 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $533.22 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $417.31 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $396.77 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $365.72 | 2019-2025 | |
| Amarin Pharma, INC. | $324.30 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $289.60 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Sanofi-Aventis U.S. LLC | $224.58 | 2020-2023 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $185.28 | 2020 | |
| Lundbeck LLC | $147.19 | 2021-2025 | Vyepti, Rexulti |
| Abbott Laboratories | $143.74 | 2019-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $137.68 | 2024-2025 | Sunosi, Auvelity |
| Otsuka America Pharmaceutical, INC. | $133.37 | 2023-2025 | Rexulti |
| Esperion Therapeutics, INC. | $127.92 | 2022-2025 | Nexletol |
| Insmed, INC. | $125.13 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $117.72 | 2021 | |
| Exact Sciences Corporation | $99.73 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $99.60 | 2019-2024 | Eliquis, Camzyos |
| Sumitomo Pharma America, INC. | $97.33 | 2023-2025 | Gemtesa |
| Corcept Therapeutics | $96.83 | 2022-2025 | Korlym |
| Gilead Sciences, INC. | $73.51 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $71.60 | 2025 | Zenpep |
| Neurocrine Biosciences, INC. | $69.44 | 2024-2025 | Ingrezza |
| Phadia US INC. | $54.07 | 2019-2025 | Immunocap |
| Seqirus USA INC | $52.64 | 2024-2025 | Flucelvax, Fluad |
| Teva Pharmaceuticals USA, INC. | $50.55 | 2019-2020 | |
| Ibsa Pharma INC. | $44.98 | 2020-2021 | |
| Inspire Medical Systems, INC. | $44.66 | 2025 | Inspire |
| Baxter Healthcare | $43.52 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.11 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.22 | 2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $39.06 | 2022 | |
| Eisai INC. | $34.98 | 2021 | |
| Phathom Pharmaceuticals, INC. | $34.25 | 2024-2025 | Voquezna |
| Dexcom, INC. | $33.39 | 2025 | Dexcom G6 Transmitter |
| Jazz Pharmaceuticals INC. | $30.41 | 2021-2022 | |
| Bausch Health US, LLC | $23.93 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $23.73 | 2023 | Opsumit |
| Regeneron Healthcare Solutions, INC. | $23.61 | 2019 | |
| Horizon Therapeutics Plc | $16.20 | 2020 | |
| Vistapharm, INC. | $14.34 | 2021 | |
| Insulet Corporation | $12.91 | 2023 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Saedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.